Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study
Authors' conclusion
Observed event rates for ischaemic events and bleeding generally align with those in the pivotal trials, support the established safety profile of ticagrelor, and highlight the significant residual ischaemic risk in this population.
Study context
- Population
- Patients with prior MI initiating extended DAPT with ticagrelor 60 mg, US and European register and claims data95% prior ticagrelor 90 mg
- Participants
- 7,035 patients
- Outcome
- Cumulative incidence of MI, stroke or all-cause mortality; bleeding requiring hospitalization
- Follow-up
- 12 months from initiation of ticagrelor 60 mg
Methodological detailsmulti-country, register and claims data, meta-analysis of data sources
- Multi-country
- Register and claims data
- Meta-analysis of data sources
Main finding
As reported in the abstract
MI, stroke or mortality (cumulative incidence) · 12 months
Ticagrelor 60 mg
3.33%
cumulative incidence · 95% CI 2.73–4.04
Observational data: associations, not effects.
Safety
| Outcome | Values |
|---|---|
| Bleeding requiring hospitalization (cumulative incidence) · 12 months | Ticagrelor 60 mg cumulative incidence 0.96% (95% CI 0.69–1.33) |
Original publication
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. Eur Heart J Cardiovasc Pharmacother. Published 31 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it